Physician profile
Lilian Jalil
NPI 1720084296
$1,436.96
in general payments reported to CMS, 2019-2025
19 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2024: $326 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $315.32 | 2019-2025 | |
| Abbvie INC. | $311.54 | 2024-2025 | |
| Astellas Pharma US INC | $147.35 | 2024-2025 | Veozah |
| Inspire Medical Systems, INC. | $102.76 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $85.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $78.13 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $69.13 | 2019-2025 | Wegovy |
| Amgen INC. | $59.65 | 2019 | |
| Exact Sciences Corporation | $53.99 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.51 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $33.08 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.16 | 2025 | Onpattro |
| Almatica Pharma LLC | $25.95 | 2025 | Teriparatide, Loreev Xr |
| Intra-Sana Laboratories | $18.16 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Otsuka America Pharmaceutical, INC. | $17.12 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2024 | Airsupra |
| Merck Sharp & Dohme LLC | $13.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilian Jalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.